Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruder, Dennis, Papadimitrakopoulou, Vassiliki, Shien, Kazuhiko, Behrens, Carmen, Kalhor, Neda, Chen, Huiqin, Shen, Li, Lee, J. Jack, Hong, Waun Ki, Tang, Ximing, Girard, Luc, Minna, John D., Diao, Lixia, Wang, Jing, Mino, Barbara, Villalobos, Pamela, Rodriguez-Canales, Jaime, Hanson, Nana E., Sun, James, Miller, Vincent, Greenbowe, Joel, Frampton, Garrett, Herbst, Roy S., Baladandayuthapani, Veera, Wistuba, Ignacio I., Izzo, Julie G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188056/
https://www.ncbi.nlm.nih.gov/pubmed/30338041
http://dx.doi.org/10.18632/oncotarget.26129

Ejemplares similares

Ejemplares similares